If kevetrin and prurisol are shown to work, I don't believe Pfizer or Merck will care what exchange ctix is or isn't on.  It just won't matter to them.  Why would it?

If wanting to self license and go on their own they'd probably do better with an uplist down the road, but, I don't see any reason to do so if a buyout is the goal.  The window dressing doesn't matter if the darn drugs work.

And, as a shareholder, I hope they don't consider it until the price is in the $10 range.